Cancer cell therapy company Arcellx opened up 78%, marking the largest intraday gain for a U.S. IPO, and Gilead Sciences will acquire the company at a price of $115 per shareWallstreetcn·Feb 23 at 02:35 PMFBT-1.14%IBBQ-1.24%
The Nasdaq Biotechnology Index fell by 2%. Among the constituent stocks, Jyong Biotech dropped by 20.95%, BridgeBio Pharma fell by 15.21%, Sionna Therapeutics decreased by 15.12%, Abcellera Biologics declined by 14.98%, and Editas Medicine fell by 14.62%. Gilead Sciences rose by 2.15%, Silence Therapeutics increased by 5.12%, Erasca went up by 5.69%, and Phibro Animal Health surged by 22.02%Wallstreetcn·Feb 5 at 11:56 PMXLV-0.25%ARKG+0.10%
